Pull to refresh
Logo
Scientists map an immune-cell 'tipping point' that may decide who develops Alzheimer's dementia

Scientists map an immune-cell 'tipping point' that may decide who develops Alzheimer's dementia

New Capabilities

A brain-tissue study points to microglia as the switch between resilience and decline—and a drug targeting that switch is already in human trials.

July 26th, 2026: Findings reach a wide public audience

Overview

Updated Jul 27

Many people carry amyloid plaques in their brains and never lose their memory. Others with similar plaques slide into dementia. A June 2026 study in Nature Medicine says the difference comes down to how the brain's immune cells respond when amyloid meets tau protein.

Researchers at VIB, KU Leuven, the UK Dementia Research Institute and Muna Therapeutics traced how microglia shift behavior at that crossover point. That shift is now a drug target. Muna is running a Phase 1 trial of MNA-001, an oral TREM2 agonist designed to hold microglia in a protective state, with safety data due in late summer 2026.

Why it matters

If microglia are the switch, future drugs could protect memory in people who already have plaques, not just clear the plaques themselves.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

55M+
People living with dementia worldwide
The global population the research aims to help protect.
6
Tissue states mapped in brain samples
Distinct stages the team traced across donated brain tissue.
~30 yrs
Amyloid's reign as the main drug target
The plaque-clearing approach has dominated Alzheimer's research since the 1990s.
€2.5M
European Research Council grant
Funding for the CELLPHASE_AD project behind the work.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

April 1992 July 2026

8 events Latest: July 26th, 2026 · 2 months ago
Tap a bar to jump to that date
  1. Findings reach a wide public audience

    Latest Public revelation

    Science news outlets cover the tipping-point study, spotlighting microglia and TREM2 as fresh treatment targets.

  2. Study published in Nature Medicine

    Scientific milestone

    The team reports a microglial 'tipping point' where amyloid meets tau, and maps two paths to brain resilience.

  3. Alzheimer's Association awards Muna Therapeutics $1M to advance MNA-001 trial

    Funding

    The Alzheimer's Association granted $1 million to Muna Therapeutics to support its ongoing Phase 1 trial of MNA-001 and to validate TREM2 biomarkers ahead of Phase 2 planning.

  4. Muna Therapeutics doses first subjects in Phase 1 trial of MNA-001

    Clinical milestone

    Muna Therapeutics announced that first healthy adult subjects had received MNA-001, an oral TREM2 agonist, in a randomized, double-blind, placebo-controlled Phase 1 study. The trial tests safety, tolerability, and biomarker evidence of TREM2 engagement in plasma and cerebrospinal fluid.

  5. FDA approves donanemab

    Regulatory

    A second anti-amyloid antibody, donanemab (Kisunla), wins approval. Both drugs slow decline modestly and carry brain-swelling risks.

  6. FDA fully approves lecanemab

    Regulatory

    The U.S. Food and Drug Administration grants full approval to the plaque-clearing drug lecanemab, sold as Leqembi.

  7. TREM2 linked to Alzheimer's risk

    Scientific milestone

    Studies tie variants in the TREM2 gene, which governs microglia, to higher Alzheimer's risk. Immune cells enter the picture.

  8. Amyloid hypothesis takes hold

    Scientific milestone

    Researchers propose that amyloid-beta buildup drives Alzheimer's. It shapes drug development for the next three decades.

Scenarios

1

Independent lab confirms the microglial tipping point

Likely Resolves by Q2 2028

Discussed by: VIB-KU Leuven researchers; dementia research groups following the work

The map of six tissue states and the amyloid-to-tau microglial switch is striking, but it rests on donated brain tissue analyzed by one collaboration. Another group reproduces the core finding in separate brain samples, giving drug developers confidence the switch is real and worth targeting.

2

A microglia-targeting drug enters human trials

Possible Resolves by Jul 31, 2029

Discussed by: Muna Therapeutics; industry analysts tracking Alzheimer's pipelines

The study hands companies like Muna Therapeutics a concrete target: the microglial switch and pathways such as TREM2. If preclinical work holds, a compound designed to keep microglia in a protective state, or to delay the harmful shift, is registered for a clinical trial in Alzheimer's patients.

3

The target stalls before reaching patients

Uncertain Resolves by Jul 31, 2029

Discussed by: Skeptics of past immune-targeting attempts, citing the failed TREM2 agonist AL002

Microglia have burned drug developers before. Alector's TREM2 agonist AL002 missed its main goals in a Phase 2 trial reported in late 2024. The tipping-point finding may prove hard to drug, or interventions may work only in a narrow window before tau spreads, leaving the idea stuck in the lab.

4

MNA-001 Phase 1 readout confirms safety and TREM2 engagement

Possible Resolves by End of 2026

Discussed by: Muna Therapeutics; Sofinnova Partners; Alzheimer's Association grant committee

Muna's Phase 1 trial tests MNA-001 for safety, tolerability, and biomarker evidence that the drug reaches and activates TREM2 in the brain. If late-summer 2026 data confirms an acceptable safety profile and measurable TREM2 engagement, Muna advances to a Phase 2 efficacy trial. That would be the first direct test of whether holding microglia in a protective state slows cognitive decline.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

June 2021

Aducanumab's contested approval (2021)

The FDA approved the anti-amyloid drug aducanumab (Aduhelm) despite an advisory panel voting against it. Several panel members resigned in protest. The drug cleared plaques but showed unclear benefit for memory.

Then

Insurers restricted coverage and the rollout largely failed. Its maker later pulled the drug from the market.

Now

The episode hardened doubts that clearing amyloid alone reliably helps patients, opening room for other targets.

Why this matters now

The tipping-point study offers an answer to that doubt: the immune response to plaques, not the plaques alone, may decide who declines.

November 2024

TREM2 agonist AL002 misses in Phase 2 (2024)

Biotech firm Alector reported that AL002, a drug meant to boost microglia through the TREM2 pathway, failed to slow decline in its Phase 2 trial. It was one of the first big tests of directly drugging brain immune cells.

Then

Alector deprioritized the program, and enthusiasm for simple TREM2 activation cooled.

Now

The result showed that timing and the specific microglial state likely matter more than just switching immune cells on.

Why this matters now

This study suggests why blunt approaches struggle: there is a narrow window before microglia flip to a harmful state near tau.

Sources

(7)